TCIM-based therapies have tremendous promise for the treatment of Alzheimer’s disease, as they can target most of the pathogenic pathways, such as oxidative stress, inflammation, tau pathology, and cholinergic deficits. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.